Ascendia

]

  MARKET NEWS

MGS Acquires European-Based Medical Injection Molder Knudsen Plast A/S
TARA-002 Demonstrates 68% Complete Response Rate at 6 Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
etherna´s Intratumoral mRNA/LNP Platform Advances to Clinical Testing in Nonmelanoma Skin Cancer Led by Almirall
SolasCure Completes Phase 2 Clinical Trial Demonstrating Accelerated Healing With Aurase Wound Gel
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor
Global Pain Market Presents Significant Opportunities for Novel Mechanisms & Modalities
SGS Receives Regulatory Approval to Restart Human ¹⁴C ADME Trials
Lonza Strengthens Advanced Synthesis Capabilities to Lead Bioconjugates Innovation & Development
Proveris Laboratories Launches Redesigned Website Focused on Analytical Clarity in OINDP Development
RoukenBio & AVS Bio Announce Strategic Partnership to Integrate Design-Focused Antibody Discovery & OptimiZation With Mechanism-Driven Functional Characterization

  EXPERT CONTENT & RESOURCES

Jinying Ning, PhD

Drug Combination Screening in Oncology: Advancing Predictive Strategies for Precision Drug Development

Jinying Ning, PhD, reports combination therapy is no longer an optional strategy in oncology drug development. The biological complexity of cancer demands approaches that account for pathway redundancy, adaptive resistance, and tumor heterogeneity.

How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?

How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?

Low bioavailability due to poor API solubility is one of the major challenges to be overcome when developing oral dosage form drug products. An effective way of addressing this problem is to transform low solubility APIs into amorphous solid dispersions (ASDs) and can often be achieved via hot melt extrusion (HME).

Single B Cell Antibody Discovery: Improving Therapeutic Candidate Selection in Drug Development

Single B Cell Antibody Discovery: Improving Therapeutic Candidate Selection in Drug Development

Changchun Zha says as therapeutic pipelines become more complex, technologies that combine biological relevance with molecular accuracy are shifting from helpful additions to essential capabilities. Single B cell antibody discovery supports this transition by capturing naturally occurring antibodies, preserving native chain pairing, and producing sequence-defined candidates from the beginning.

  FEATURED EDITORIAL

  COMPANY PROFILE

NIPRO PharmaPackaging specializes in developing and manufacturing advanced primary packaging solutions and strives to be the preferred and trusted partner for pharmaceutical companies worldwide in the safe delivery of parenteral medicines to patients. NIPRO PharmaPackaging is part of NIPRO Corporation Japan, established in 1954. As a leading global healthcare company with over 39.000+ employees worldwide, NIPRO serves the Pharmaceutical, Medical Device, and Pharmaceutical Packaging industries. Click here for more.

  WHITEPAPERS & WEBINARS

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

       
By:
Harry Wade, Technical Associate, and Rosie Bird, EHS Lead, Catalent Dartford

The pharmaceutical industry faces a growing manufacturing challenge as therapeutic compounds become increasingly potent and targeted. Oncology and hormonal APIs, often designed for ultra-low dosing, promise meaningful clinical …

WHITEPAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations

WHITEPAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations

Abstract

Intradermal delivery has long been a critical method in medical and pharmaceutical fields, offering unique advantages for diagnosis, vaccination and therapeutic applications. This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as …

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

WHITEPAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers

 

The biopharmaceutical classification system classifies drugs according to their permeability and solubility. Drugs with poor solubility and/or permeability are class II or IV type drugs, and these require special formulation technologies for solubility enhancement. In the past 25 …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 4 – Drug Delivery
March 11 – Parental Contract Manufacturing